Insider Trading Fri 5/24/24

Notable purchases -- CEO adds to COOK; notable sales -- Director active in AVT 

Buyers:

• COOK Chief Executive Officer bought 228,323 shares at $2.11 - $2.25 worth approx. $500K.
• CTRN 10% owner bought 50,406 shares at $22.07 - $22.96 worth approx. $1.1 mln.
• ELAN Director bought 15,000 shares at $16.98 worth ~$255K.
• EPSN Chief Executive Officer bought 26,000 shares at $5.35 - $5.38 worth nearly $140K.
• FOUR Chairman & Chief Executive Officer bought 39,135 shares at weighted average price of $64.0375 worth about $2.5 mln.
• NCLH Director bought 20,000 shares at $16.25 - $16.50 worth approx. $328K.
• OPK Chairman & Chief Executive Officer bought 100,000 shares at $1.26 - $1.27 worth ~$127K.
• SBRA Director bought 7,000 shares at $14.43 worth ~$101K.
• VSTS 10% owner Corvex Management bought 100,000 shares at $12.08 - $12.19 worth more than $1.2 mln.

Sellers:

• AVT Director sold 9,000 shares at $54.20 - $54.61 worth approx. $490K.
• ZWS 10% owner sold 48,388 shares at $32.91 - $32.98 worth ~$1.6 mln.

Insider Trading Tue 1/30/24

Notable purchases -- 10% owner adds to KALV; notable sales -- COO active in SSB

Buyers:

• FBK Director bought 14,808 shares at $24.77 - $29.61 worth ~$399K.
• KALV 10% owner bought 91,804 shares at $12.64 - $14.43 worth ~$1.3 mln.
• OPK Director bought 30,000 shares worth ~$30K.

Sellers:

• BFH 10% owner sold 45,000 shares at $35.11 - $36.23 worth ~$1.6 mln.
• CBU Director sold 3,501 shares at $48.76 worth ~$171K.
• SLB Chief Sustainability Officer sold 8,000 shares at $52.625 worth ~$421K.
• SSB Chief Operating Officer sold 4,025 shares at $85.62 worth ~$345K.

Other notable transactions:

• NFLX co-founder / executive chairman Reed Hastings gifted 2,000,000 shares of Netflix common stock worth more than $1.1 bln (based on yesterday's closing price). Hastings now owns owns approx. 2.99 mln shares. 

Insider Trading : Tue 8/8/23

Notable purchases -- President/CEO adds to CERE; notable sales -- HR Chief active in CME

Buyers:

• BY 10% owner bought 20,000 shares at ~$21.6258 worth ~$433K.
• CERE President & CEO and one (1) Director bought a total of 105,737 shares at $22.85 - $24.01 worth ~$2.5 mln.
• EPD Director bought 50,000 shares at $26.57 -  $26.63 worth ~$1.3 mln.
• GABC Director bought 5,869 shares at $30.67 worth ~$180K.
• HBB President & CEO bought 10,000 shares at $10.59 worth ~$106K.
• OPK CEO & Chairman bought 650,000 shares at $1.815 - $1.86 worth ~$1.2 mln.
• STAA Director bought 2,000 shares at $48.72 worth ~$97K.
• SUP 10% owner Mill Road Capital bought 77,258 shares at $3.5865 - $3.8111 worth ~$284K.

Sellers:

• CME Senior Managing Director & Chief Human Resources Officer sold 4,477 shares at $207.98 worth ~$931K.
• MOH EVP, Health Plans sold 2,523 shares at $312.72 worth ~$789K.
• TZOO 10% owner Azzurro Capital sold 140,000 shares at $7.31 - $7.80 worth ~$1.0 mln.

Insider Trading (Wed 6/8/22)

Notable purchases -- CEO and Director add to KPLT; notable sales -- Director active in NCNO

Buyers:

• CBAY CEO bought 51,301 shares at $1.95 worth ~ $100K.
  
• CGEM CEO bought 8,090 shares at $12.34 - $12.45 worth ~ $100K.
  
• COMM CFO bought 17,887 shares at $8.09 - $8.11 worth ~ $140K.
  
• HRT Director bought 29,991 shares at $14.85 - $14.99 worth ~ $450K.
  
• KIND Director bought 5,837,072 shares at $3.03 - $3.62 worth ~ $19.4 mln.
  
• KPLT CEO and Director bought 278,472 shares at $1.38 - $1.57 worth ~ $430K.
  
• LGF.B Director bought 58,687 Class B common shares at $9.12 - $9.81 worth ~ $560K.
  
• OPK CEO & Chairman bought 100,000 shares at $2.77 - $2.82 worth ~ $280K.
  
• PDLB CFO and Executive Chairman bought 12,000 shares at $9.23 - $9.25 worth ~ $110K.

Sellers:

• BMY EVP, General Counsel sold 65,000 shares at $74.87 - $74.91 worth ~ $4.9 mln.
  
• FEAM 10% Owner sold 500,000 shares at $25.00 - $25.01 worth ~ $12.5 mln.
  
• FLYW Director sold 1,240,490 shares at $19.60 worth ~ $24.3 mln.
  
• GPN Senior EVP & General Counsel sold 16,252 shares at $129.95 - $130.29 worth ~ $2.1 mln.
  
• MDRX Director sold 140,450 shares at $17.30 - $17.40 worth ~ $2.4 mln.
  
• NCNO Director sold 100,000 shares at $35.00 - $37.14 worth ~ $3.6 mln.
  
• PCOR Director sold 54,378 shares at $46.14 - $47.42 worth ~ $2.5 mln.
  
• RPTX Director sold 750,000 shares at $12.25 - $12.50 worth ~ $9.2 mln.

OPK — is it a buy?

• March 21: #5; Is OPK a buy? 

 

• 6 weeks later: NO

-=Opko Health (OPK) announces proposed resolution of SEC action

Opko Health announces proposed resolution of SEC action

• In a settlement, subject to court approval, OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, have agreed with the Securities and Exchange Commission to resolve the action brought against them in the litigation SEC v. Honig et al.
• Without admitting or denying the SEC's allegations, OPKO agreed to an injunction from certain violations of the Securities Exchange Act of 1934; a $100,000 penalty; and will perform certain undertakings related to the Exchange Act. Dr. Frost agreed, without admitting or denying the SEC's allegations, to injunctions from certain violations of the Securities Act of 1933 and the Exchange Act; approx. $5.5 mln in penalty, disgorgement, and prejudgment interest; and a prohibition, with certain exceptions, from trading in penny stocks.
• Dr. Frost will continue to serve as CEO and Chairman.

=Opko Health (OPK) reported earnings on Fri 9 Nov 2018 (a/h)

Opko Health beats by $0.01, misses on revs

• Reports Q3 (Sep) loss of $0.05 per share, $0.01 better than the two analyst estimate of ($0.06); revenues rose 1.6% year/year to $250 mln vs the $264.04 mln S&P Capital IQ Consensus, including $5.8 million from RAYALDEE; revenues from services were $202.8 million for the 2018 period compared with $200.9 million last year.

MIAMI (AP) _ Opko Health Inc. (OPK) on Friday reported a loss of $27.7 million in its third quarter.

The Miami-based company said it had a loss of 5 cents per share.

The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 8 cents per share.

The holding company with investments in pharmaceutical and diagnostics companies posted revenue of $249.8 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $262.5 million.

In the final minutes of trading on Friday, the company's shares hit $3.11. A year ago, they were trading at $5.42.

Opko Health (OPK) reported earnings Mon 9 Nov 2015 (after close)

** charts before earnings **

 ** charts after earnings **

 Opko Health: Co beats by $0.26, beats on revs:

• Reports Q3 (Sep) earnings of $0.25 per share, $0.26  better than the Capital IQ Consensus of ($0.01); revenues rose 622.2% year/year to $143 mln vs the $133.04 mln Capital IQ Consensus.
• Rayaldee PDUFA Date is March 29, 2016; "Our NDA filing for Rayaldee continues to advance through the FDA drug approval process and we have high expectations for our new treatment option for patients with stage 3 or 4 chronic kidney disease and secondary hyperparathyroidism."
• Completed Enrollment in Ongoing Phase 3 Trial in Growth Hormone Deficient Adults
• Cash, cash equivalents and marketable securities were $212.1 million as of September 30, 2015.

Great trade : OPK +25% (5/15)

• 12 May 2015:   #3      $14.50
• 20 May     $18